Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial

Venetoclax in patients with relapsed/refractory del(17p) CLL resulted in an ORR of 79% (7% CR) at the initial analysis of the M13-982 trial (n=107). Subsequently, 51 patients were enrolled in a safety expansion cohort.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: William Wierda, Brenda Chyla, Barbara Eichhorst, Johannes Schetelig, Talha Munir, Peter Hillmen, John F. Seymour, Andrew W. Roberts, Steven Coutre, Wojciech Jurczak, Stephen P. Mulligan, Clemens-Martin Wendtner, Matthew Davids, Sebastian B öettcher, Elis Source Type: research